Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
17,990
-40 (-0.22%)
Sep 1, 2026, 3:30 PM KST

Onconic Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
24,25115,784-8,0931,682-14,432-15,149
Depreciation & Amortization
567.28528.44452.67460.13199.66181.88
Other Amortization
----1.181.08
Loss (Gain) From Sale of Assets
---0.7--
Stock-Based Compensation
1,637696.531,026578.03472.48163.17
Other Operating Activities
-3,097-2,2554,427-774.88-277.646,829
Change in Accounts Receivable
-9,749-3,647-7,222104.5-99-5.5
Change in Accounts Payable
2,1731,961708.67---
Change in Income Taxes
-22.39-463.39---
Change in Other Net Operating Assets
1,045-1,673396.572,089-825.75-879.32
Operating Cash Flow
16,80611,395-7,8414,140-14,961-8,859
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-316.64-302.9-141.28-1,157-2,575-2.67
Sale of Property, Plant & Equipment
---38--
Sale (Purchase) of Intangibles
------5.88
Investment in Securities
-4,894-5,894----
Other Investing Activities
-13.64-70.42108.76135.75-
Investing Cash Flow
-5,224-6,197-70.85-1,011-2,439-8.55

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--194.35-179.92-153.85-142.06-142.06
Net Debt Issued (Repaid)
-203.25-194.35-179.92-153.85-142.06-142.06
Issuance of Common Stock
2,8851,27919,762--7,498
Other Financing Activities
-1,611-1,611-114--
Financing Cash Flow
1,071-526.2719,582-39.8525,85827,356

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
319.35-625.721,229-196.39--
Miscellaneous Cash Flow Adjustments
----108.76--
Net Cash Flow
12,9734,04612,8992,7848,45818,488

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
16,49011,092-7,9822,983-17,536-8,861
Free Cash Flow Growth
------
Free Cash Flow Margin
20.07%20.77%-53.79%14.16%-18458.96%-14769.11%
Free Cash Flow Per Share
-244.50-244.07129.01-758.49-386.90
Levered Free Cash Flow
5,1185,103-50,06216,30413,630-
Unlevered Free Cash Flow
5,1245,111-49,64617,41314,304-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
871.38959.21912.062,1702.182.71
Change in Working Capital
-6,553-3,359-5,6532,193-924.75-884.82